<DOC>
	<DOCNO>NCT00741364</DOCNO>
	<brief_summary>There much interest understand role vitamin D3 ( cholecalciferol ) play various cancer , prognosis various cancer discover . The purpose study examine effect vitamin D prostate cancer-associated lesion vitamin D metabolite prostate tissue . We give vitamin D3 men schedule prostate remove cancer . The men take vitamin D one 3 dos 4-6 week , surgery perform . We compare prostate tissue take men receive high dos vitamin D tissue men assign low dos . We expect find prostate remove surgery men receive high-dose vitamin D treatment appear normal , less cancer like . In addition , measure vitamin D metabolites prostate confirm accumulate prostate bring effect observe .</brief_summary>
	<brief_title>Vitamin D Effects Prostate Pathology</brief_title>
	<detailed_description>Epidemiologic , laboratory , clinical report suggest vitamin D3 ( cholecalciferol ) play desirable role prevention prognosis prostate cancer . Prostate cancer cell possess enzymes required convert vitamin D active paracrine hormone , calcitriol . However , dose-response relationship serum level calcidiol ( vitamin D status ) prostate tissue level calcidiol calcitriol yet define . As neoadjuvant , prior radical prostatectomy ( 4-6 wk ) vitamin D3 [ 400 IU ( control group ) , 10,000 IU 40,000 IU/day ] give 90 men randomize , double-blinded , 30 per dose . Immediately surgery , pathologist obtain grams prostate tissue , use assay calcidiol calcitriol within prostate . From embedded prostate , prepare immunohistochemically stained section characterize cellular response morphological change . Our hypothesis vitamin D increase intraprostate calcitriol concentration thereby low cellular proliferation ( judged marker MIB-1 p27 ) zone Gleason pattern 3 prostate cancer pre-cancerous ( PIN ) lesion . We expect result provide surrogate outcome justify large trial vitamin D treatment prostate cancer . This research potential : 1 . Provide direct evidence cellular level use clinical sample vitamin D lower cellular proliferation prostate cancer , 2 . Provide guidance serum calcidiol concentration ( thereby vitamin D dos ) target study , 3 . Eventually support research direct vitamin D primary prevention strategy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Diagnosis Gleason score 6 7 adenocarcinoma prostate biopsy Patient elect radical prostatectomy Patient determine fit surgery Normal renal hepatic function Normal serum urine calcium value Normal serum phosphate value Normal serum parathyroid hormone value Signed write informed consent Prior use neoadjuvant androgen deprivation therapy Prior use 5 alpha reductase inhibitor ( finasteride dutasteride ) last 12 month Previous concomitant anticancer therapy ( chemotherapy , radiotherapy ) Gleason score 810 adenocarcinoma biopsy diagnosis History hypercalcemia/hypercalciuria History renal disease History sarcoidosis Vitamin D ( cholecalciferol ) supplement &gt; 1000 IU/day Inability comply study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostatectomy</keyword>
	<keyword>pathology</keyword>
	<keyword>immunohistochemistry</keyword>
</DOC>